» Articles » PMID: 6204749

Immunohistochemical Analysis of Malignant Melanomas and Nevocellular Nevi with Monoclonal Antibodies to Distinct Monomorphic Determinants of HLA Antigens

Overview
Journal Cancer Res
Specialty Oncology
Date 1984 Sep 1
PMID 6204749
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Using an indirect immunoperoxidase technique, 20 nevocellular nevi, 5 dysplastic nevi, 14 primary cutaneous melanomas, and 24 metastatic melanomas were tested with a panel of monoclonal antibodies to monomorphic determinants of Class I (HLA-A,B,C) and Class II (la-like) major histocompatibility complex antigens. Class I HLA and beta 2-microglobulins were not detected on the majority of nevus cells but were expressed by 3 of 5 dysplastic nevi, by the majority of tumor cells in 12 of 14 primary cutaneous melanomas, and in 13 of 24 metastases. The different expression of Class I HLA and beta 2-microglobulins in primary and metastatic lesions suggests that loss of these antigens may be associated with progression of malignancy. Class II HLA were not detected in common nevi but were locally present in 1 of 5 dysplastic nevi, 7 of 14 cases of primary cutaneous melanoma, and all 24 cases of metastatic lesions tested. These findings suggest that increase in Class II HLA expression may be associated with progression of malignancy. The staining patterns obtained with monoclonal antibodies to distinct determinants of Class I HLA and Class II HLA were superimposable within each type of antigen. Therefore, the discrepancies in the literature about the expression of histocompatibility antigens by lesions of melanocytic origin are not likely to reflect the different specificity of the antibodies used by the various investigators.

Citing Articles

MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy.

Baleeiro R, Bouwens C, Liu P, Di Gioia C, Chard Dunmall L, Nagano A Oncoimmunology. 2022; 11(1):2080329.

PMID: 35655709 PMC: 9154752. DOI: 10.1080/2162402X.2022.2080329.


Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.

Dhatchinamoorthy K, Colbert J, Rock K Front Immunol. 2021; 12:636568.

PMID: 33767702 PMC: 7986854. DOI: 10.3389/fimmu.2021.636568.


Identification of bacteria-derived HLA-bound peptides in melanoma.

Kalaora S, Nagler A, Nejman D, Alon M, Barbolin C, Barnea E Nature. 2021; 592(7852):138-143.

PMID: 33731925 PMC: 9717498. DOI: 10.1038/s41586-021-03368-8.


Discovery and Validation of a Metastasis-Related Prognostic and Diagnostic Biomarker for Melanoma Based on Single Cell and Gene Expression Datasets.

Wan Q, Liu C, Liu C, Liu W, Wang X, Wang Z Front Oncol. 2020; 10:585980.

PMID: 33324561 PMC: 7722782. DOI: 10.3389/fonc.2020.585980.


Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment.

Wang H, Zhao S, Zhang X, Jia K, Deng J, Zhou C Onco Targets Ther. 2019; 12:7281-7288.

PMID: 31564911 PMC: 6733341. DOI: 10.2147/OTT.S214231.